Monday, 28 May 2018

RA/Inflammatory arthritis

Datesort ascending Type Title Save
05 Apr 2018 Social Swiss study of 244 pregnancies finds RA and axSpA have significantly higher risk of pregnancy complications (DM, preeclampsia, infection, small babies, preterm delivery). Active disease predicts preterm delivery in both RA (OR 3.9) & axSpA (OR 13.8) https://t.co/I02unIG499
05 Apr 2018 Social EMR study of 116 obese/overweight RA clinic pts shows that the 31% lost ≥5 kg during follow-up had 3 fold chance of disease activity improvement (CDA >5). https://t.co/JIanV3FuE8
05 Apr 2018 Social 2 RA Cohorts compared 1996 (T1) & 2006 (T2). Total cost of care similar from T1 to T2 (EUR 13280 v 12342), Dz activity, sick leave & hospitalization decreased, yet DMARD & drug cost increased. Loss of productivity is the largest part of total costs. https://t.co/OuIyQwGSjv
03 Apr 2018 Social RT @KearsleyFleet: #publicationanniversary Looking back to the @BSRBR_RA publication from last year: "Rates of live births were reassuring…
03 Apr 2018 Social 3 million have IBD in USA. New study of 22 million IBD pts shows a 2 fold greater risk of MI (5.9% vs 3.5% without IBD). https://t.co/UACAiTfAAt
03 Apr 2018 Social RT @jrheum: Ocular Involvement in Sarcoidosis https://t.co/4QnuHZ1lX2 #sarcoidosis #eye #vision https://t.co/ml3RXpysyE
03 Apr 2018 Social Claims analyses from Medicare, IMS PharMetrics & MarketScan (2010-15) looked at CV outcomes in RA pts starting tocilizumab (6,237) or abatacept (14,685) & finds no difference in CV risk (HR 0.82; 0.55–1.22) (TCZ vs ABA) https://t.co/jNnOCDvX2u
02 Apr 2018 Social 56 myositis patients with anti‐NXP‐2 autoantibodies (18 with and 38 without calcinosis) showed that NXP‐2 Ab levels correlate w/ disease activity, espcially in those without calcinosis; suggesting calcinosis defines 2 phenotypes. https://t.co/1BhJeWTMgv
02 Apr 2018 Social UK study of 2386 early RA patients showed Obesity prevalence is rising and is linked to worse disease activity, function, HRQOL. The data argue strongly for obesity management to be integrated into RA care https://t.co/ZEVSKDcBon
01 Apr 2018 Social RT @RajkiranDudam: #Vasculitis @alfredmahr https://t.co/dLQfqRYtmr
29 Mar 2018 News Precision Genetics Can Predict Methotrexate Non-Responders
29 Mar 2018 Social Epigenetic architecture changes represented by a chromosome conformation signatures (IFNAR1, IL-21R, IL-23, CXCL13, IL-17A) can accurately PREDICT MTX Nonresponse in 90% of early RA pts (N=59) . https://t.co/FQPwcOffsT
27 Mar 2018 Social IL-37 is elevated in active adult-onset Still's disease and may be a biomarker of AOSD activity. IL-37 correlates with systemic score, IL-1β, IL-18, and IL-10. IL-37 is an antiiinflammatory cytokine that inhibits IL-18 activity. https://t.co/IFQrOpBKdi
25 Mar 2018 Social FDA Arthritis Advisory Committee tomeet on April 23rd to discuss the NDA for Eli Lilly's JAK inhibitor - baricitinib in moderate to severe RA. Discussion will be around risk:benefit assessment, dose selection & the risk of venous thromboembolic events. https://t.co/dQ4AdYZyQx
25 Mar 2018 Social The RheumNow Week in Review is up on the website https://t.co/uZJI2SoWlL ; or listen to the podcast on your iPhone, iTunes or here https://t.co/3KCu2GjosR
22 Mar 2018 Social Norfolk registry study of 431 inflammatory arthritis pts shows 82% still on MTX after 2 years. Early MTX failure associated with RF+, younger onset age, high DAS-28. MTX D/C for AE less likely if RF-positive https://t.co/kOrfaCnZaf
21 Mar 2018 Social Study from German RABBIT Registry of 885 RA patients treated with tocilizumab finds that treatment success with TCZ similar in pts with no, 1 or 2 prior bDMARD failures, but less with with ≥ 3 bDMARD failures. https://t.co/jAriEaPruP
20 Mar 2018 Social FDA Arthritis Advisory Committee will meet on April 23rd to discuss the NDA for Eli Lilly's JAK inhibitor - baricitinib in moderate to severe RA. Discussion will be around risk:benefit assessment, dose selection & the risk of venous thromboembolic events. https://t.co/dQ4AdYZyQx
19 Mar 2018 Social Flares are frequent in patients in 120 RA undergoing arthroplasty (THA, TKA); by 6 wks 63%. Flare more freq with higher disease activity (OR=2), ESR, CRP, Pain; but not affected by biologic use. https://t.co/4hdn5nTQZO
19 Mar 2018 News Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis